Celbrea
Celbrea, a Welwaze Medical brand, sells a single-use FDA-cleared thermal pad that screens for early breast disease via temperature asymmetry. Distributed by prescription through healthcare providers, it targets women including those with dense breast tissue or limited imaging access.
- Company typePrivate
- Founded-
- HeadquartersMiami, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Celbrea does
Celbrea® is a prescription-only breast health screening medical device developed and commercialized by Welwaze Medical, Inc., a private medtech company headquartered in Doral (Miami), Florida. The company's flagship product is the Celbrea® Thermal Mapping Device — a single-use disposable pad containing 1,188 nano-sensors built on photochromic liquid crystal thermographic technology. The pads are applied to each breast for approximately 15 minutes, measuring surface temperature differentials and displaying results visually through a color change (blue to red); an asymmetry of 2°F or greater is flagged as a potential thermal biomarker for underlying pathology. The device is FDA-cleared as a Class I medical device and CE Mark-approved, positioned explicitly as a complementary tool to mammography and clinical breast examination — not a replacement for imaging.
Clinically, multi-country studies (Guttman outpatient screening, Brazilian multicentric, multicentric validation) report sensitivities of 88-94% and specificity up to 98%, with a 99% negative predictive value in large screening populations. The product addresses a defined clinical gap: monitoring for women who are too young for routine mammography, those with dense breast tissue where mammography sensitivity is reduced, individuals with elevated breast cancer risk requiring frequent interim screening, and underserved populations with limited access to imaging infrastructure. Across the trial cohort (described as hundreds of thousands of women), no adverse events have been reported, and a public health initiative in Argentina recorded a 69% increase in mammography rates following Celbrea adoption.
Commercially, Celbrea generates revenue through prescription-driven sales of disposable pads distributed via a contracted network of providers — primarily gynecology, primary care, preventive medicine, and breast-specialty practices concentrated in Florida and Memphis, Tennessee, with ~10 named sites. Patients can obtain prescriptions through Celbrea's affiliated doctor network or upload existing prescriptions via the company's online platform. Pricing is structured so the product is free to eligible patients whose insurer, employer, or provider is partnered with Celbrea, with out-of-pocket payment at participating providers otherwise (specific price not publicly disclosed). Distribution extends into the EU via a separate celbrea.eu site, and clinical programs have been conducted in Brazil, Argentina, and Mexico.
Celbrea firmographics
Firmographics- Name
- Celbrea
- Legal name
- Welwaze Medical, Inc.
- Website
- https://celbrea.com
- Company type
- Private
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Celbrea, a Welwaze Medical brand, sells a single-use FDA-cleared thermal pad that screens for early breast disease via temperature asymmetry. Distributed by prescription through healthcare providers, it targets women including those with dense breast tissue or limited imaging access.
- Ownership category
- akta.pro rank
Celbrea industry classification
Industry- Product category
- Breast Health Diagnostic Medical Device
- NAICS
- Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Thermometers & Temperature Monitoring (Smart Thermometers) (CRACAQAG)
- akta.pro secondary industries
- Continuous Temperature & Fever Monitoring (Wearable Thermometry) (HLAHACAK), Mammography & Breast Imaging Systems (HLAHABAF)
Keywords
Where Celbrea is headquartered
LocationHeadquarters
- HQ city
- Miami
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Celbrea business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Technology or R&D, Marketing or Sales
Revenue model
- Disposable Medical Device Sales: Celbrea generates revenue through the sale of its single-use disposable thermal screening pads. The device is prescribed by physicians and provided to patients for breast health monitoring. Insurance coverage, employer benefits, or out-of-pocket payment options are available depending on patient eligibility.
- Prescription-Based Distribution: As a prescription-only medical device, Celbrea is distributed exclusively through licensed healthcare providers who write prescriptions for the test, creating a closed distribution model with revenue flowing through the healthcare provider network.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Insurance/Partner Covered |
| Other | Pay-as-you-go | Out-of-Pocket |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
Celbrea product offering
Product offeringCore offering
Celbrea manufactures and distributes a prescription-only, FDA-cleared breast thermal mapping medical device consisting of two single-use disposable pads embedded with 1,188 photochromic nano-sensors that detect elevated breast surface temperature as a potential biomarker for early breast disease. Applied for 15 minutes per breast, the pads visually display color changes from blue to red in real time, allowing physicians and patients to identify asymmetric thermal readings (a 2°F or greater differential) that may warrant further clinical follow-up. The device is positioned as a complementary tool to mammography and clinical breast examination, particularly for women with dense breast tissue or those not yet indicated for mammography.
Product overview
Celbrea is a single-product company offering the Celbrea® Thermal Mapping Device — an FDA-cleared, CE Mark-approved breast health monitoring device. The product consists of disposable, single-use thermal sensing pads with embedded nano-sensors that measure temperature differences on the breast surface. A significant temperature difference of 2°F or more could indicate potential underlying pathology. The device is prescription-only, used adjunct to mammography, and provides immediate real-time results through visual color display (blue to red). It is designed for women of all ages, including those with dense breasts who may not be candidates for standard mammography.
Differentiator
Problem solved
Functional benefit
Brands
- Celbrea® Thermal Mapping Device: A disposable and affordable thermal screening device consisting of two disposable pads with photochromic sensors that detects elevated temperature as a thermal biomarker for possible early breast disease detection.
Products and services
- Celbrea® Thermal Mapping Device A portable, non-invasive breast thermal screening medical device consisting of two single-use disposable pads embedded with 1,188 photochromic nano-sensors using liquid crystal thermographic technology. The pads are applied to each breast for 15 minutes and visually display color changes from blue to red in response to thermal activity, with a 2°F or greater temperature differential between breasts flagged as a possible indicator of underlying breast pathology. Intended as a prescription-only adjunct to mammography and Clinical Breast Examination for women of all ages, including those with dense breast tissue where mammography effectiveness is reduced.
Companies that use Celbrea
Customer profileNamed customers7 records
Segments5 records
Ideal customer profiles2 records
Celbrea technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Celbrea partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- PATHcoreCelbrea aligns with PATH's public health initiatives for breast health in developing countries. PATH collaborated with Peruvian Ministry of Health and regional cancer institutes on community-based breast health programs that integrated clinical breast exams, ultrasound triage, and biopsies, similar to Celbrea's mission to expand access to breast screening in underserved areas.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
Celbrea competitors and assessment
Company assessmentDirect peers
- Braster: Polish medtech company commercializing a contact liquid-crystal thermographic breast examination device (LISIA/EIR). Direct technology peer to Celbrea—both use thermographic detection for breast lesion screening and target women seeking adjunctive screening to mammography.
- Real Imaging: Israeli company developing MIRA (Multidimensional Infrared Analysis), a radiation-free, AI-assisted thermal imaging platform for breast cancer risk assessment. Closely comparable technology architecture (thermal-based) and clinical positioning as adjunctive screening to mammography.
- UE LifeSciences: Developer of iBreastExam, a radiation-free, non-invasive handheld breast lesion detection device used as a point-of-care adjunct to mammography. Most direct functional peer to Celbrea: similar patient workflow, similar adjunctive-to-mammography positioning, and comparable target customer base of OB-GYNs and primary-care physicians.
Broad incumbents
- Hologic: Major women's health medtech incumbent with leadership in mammography (3Dimensions, Genius AI) and a broad breast-health portfolio. Indirect incumbent peer: established mammography standard-of-care against which Celbrea is positioned adjunctively, with much deeper hospital integration and reimbursement infrastructure.
- Siemens Healthineers: Mammography and women's imaging incumbent (MAMMOMAT platform). Competes with Celbrea for breast-screening budgets and is a natural partner candidate for embedding adjunctive screening into broader women's-health workflows.
- GE HealthCare: Global medical imaging incumbent with a full mammography and breast-care portfolio (Senographe systems, Invenia ABUS). Provides the installed mammography base that drives Celbrea's adjunctive opportunity; relevant for partnership and competitive benchmarking.
Emerging players
- iSono Health: Developer of ATUS, an AI-enabled automated portable breast ultrasound system for point-of-care breast imaging. Comparable density-independent breast screening positioning and OB-GYN/primary-care workflow, but uses ultrasound rather than thermal detection.
- Volpara Health: Software-focused breast health analytics company providing breast density assessment and risk-stratification tools used alongside mammography. Comparable density-aware positioning and overlapping customer base (breast imaging centers, OB-GYNs); potential ecosystem partner or competitor for risk-stratified screening workflows.
- iCAD: AI-powered breast cancer detection and risk-stratification software (ProFound AI) integrated with mammography workflows. Comparable value proposition in improving early detection, especially for dense breasts; relevant as a future AI-software competitor or partner for Celbrea's data layer.
- Cyrcadia Health: Developer of the iT Bra, a wearable, AI-driven breast health monitoring patch that detects circadian temperature changes associated with early breast disease. Comparable target use case (early detection, dense-breast friendly) but differentiated by wearable/continuous-monitoring form factor versus Celbrea's 15-minute in-clinic test.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
Celbrea social profiles
Digital presenceCelbrea compliance and trust
Trust signalCompliance2 records
Celbrea financial estimates
Financial estimateRevenue estimate
Valuation estimate
Celbrea leadership team
Management profileNumber of profiles
Profiles1 record
Celbrea funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Celbrea M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Celbrea
What does Celbrea do?
Celbrea manufactures and distributes a prescription-only, FDA-cleared breast thermal mapping medical device consisting of two single-use disposable pads embedded with 1,188 photochromic nano-sensors that detect elevated breast surface temperature as a potential biomarker for early breast disease. Applied for 15 minutes per breast, the pads visually display color changes from blue to red in real time, allowing physicians and patients to identify asymmetric thermal readings (a 2°F or greater differential) that may warrant further clinical follow-up. The device is positioned as a complementary tool to mammography and clinical breast examination, particularly for women with dense breast tissue or those not yet indicated for mammography.
Is Celbrea a public or private company?
Celbrea is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Celbrea founded?
Celbrea was founded in -1. It employs 11 to 50 people.
Where is Celbrea based?
Celbrea is headquartered in Miami, United States, in the North America region.
How does Celbrea make money?
Two revenue lines are on record. Disposable Medical Device Sales are the primary driver. The others are prescription-Based Distribution.
Who are Celbrea's main competitors?
Direct peers on record are Braster, Real Imaging and UE LifeSciences. Broad incumbents are Hologic, Siemens Healthineers and GE HealthCare. Emerging players are iSono Health, Volpara Health, iCAD and Cyrcadia Health.
Does Celbrea have an API?
No public API is recorded for Celbrea.
What industry is Celbrea in?
Celbrea's product category is Breast Health Diagnostic Medical Device. Its primary akta.pro industry code is CRACAQAG, Thermometers & Temperature Monitoring (Smart Thermometers), with a secondary code of HLAHACAK, Continuous Temperature & Fever Monitoring (Wearable Thermometry). Its NAICS code is 3391 and its SIC code is 3841.